

**Disposition of Participants
(ITT Population)**

	Xanomeline High Dose	Xanomeline Low Dose	Placebo
	n	n	n
Participants randomized	84	84	86
Participants treated	84	84	86
Participants completed	27	25	58
Participants discontinued	57	59	28
Discontinued reason			
Adverse Event	40	44	8
Death	0	1	2
I/E Not Met	2	0	1
Lack of Efficacy	1	0	3
Lost to Follow-up	0	1	1
Physician Decision	2	0	1
Protocol Violation	1	1	1
Sponsor Decision	3	2	2
Withdrew Consent	8	10	9
This is footnote			

Source: [Study CDISCPilot01: adam-adsl]